Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Total Non-Current Liabilities (2023 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $14.0 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 64.75% to $14.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.0 million through Dec 2025, up 64.75% year-over-year, with the annual reading at $14.0 million for FY2025, 64.75% up from the prior year.
  • Total Non-Current Liabilities hit $14.0 million in Q4 2025 for Connect Biopharma Holdings, up from $11.9 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $14.0 million in Q4 2025 to a low of $585000.0 in Q4 2023.
  • Historically, Total Non-Current Liabilities has averaged $9.2 million across 3 years, with a median of $10.2 million in 2025.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 1350.6% in 2024 and later surged 64.75% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $585000.0 in 2023, then soared by 1350.6% to $8.5 million in 2024, then soared by 64.75% to $14.0 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for CNTB at $14.0 million in Q4 2025, $11.9 million in Q3 2025, and $11.3 million in Q2 2025.